In 2005, Congress passed the Stem Cell Therapeutic and Research Act, initiating the federally supported National Cord Blood Inventory (NCBI) program to increase the number of publicly available cord blood units for transplant. The law initially aimed to build an inventory of roughly 150,000 high-quality, diverse cord blood units to improve the likelihood of finding matches for patients in need. Today, the NCBI continues to contract with public cord blood banks across the United States, collecting and maintaining tens of thousands of units and making them searchable through the national registry for patients and physicians. [Read more…]
CHU Toulouse and Cell-Easy Launch A-MUSE, a Phase 1/2 Clinical Trial Evaluating the CellReady® Allogeneic MSC Platform in Systemic Sclerosis
Toulouse, January 22, 2026 — Cell-Easy, a CDMO specialized in the development and GMP manufacturing of Advanced Therapy Medicinal Products (ATMPs), announces a new clinical milestone achieved in close collaboration with Toulouse University Hospital (CHU Toulouse). The European Medicines Agency (EMA) has granted Clinical Trial Authorization (CTA) for AMUSE, a Phase 1/2 clinical trial evaluating the safety and efficacy of an allogeneic mesenchymal stromal cell (MSC) therapy in patients with systemic sclerosis presenting perioral fibrosis and functional impairment. [Read more…]
Embryonic Stem Cells – Definition, Uses, and Limitations
Embryonic stem cells are cells that can give rise to all of the tissues types that form a human being. These stem cells are being used in drug development, toxicology testing, and disease reversal, as well as to grow healthy new tissue to heal injuries.
While they are powerful cells, embryonic stem cells are controversial to produce, because they are created from human embryos. For this reason, they have limited use and receive restricted funding. Learn more about these cells below. [Read more…]
Novo Nordisk Foundation Commits DKK 5.5 Billion to the BioInnovation Institute (BII) through 2035
In a strategic move set to reshape the European biotech and science innovation landscape, the Novo Nordisk Foundation has pledged a long-term investment of up to DKK 5.5 billion (≈ €736 million) to the Copenhagen-based BioInnovation Institute (BII), extending support through 2035. This unprecedented investment will expand BII’s role in commercializing science, scaling startups, and building cross-sector bridges across Europe.
The commitment also signals a broader push to close Europe’s long-standing gap between world-class research and global commercial leadership in emerging technologies. [Read more…]
CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide
CAR-T cell therapy is a type of immunotherapy that teaches T cells to recognize and destroy cancer. This article provides a comprehensive list of CAR-T therapy companies worldwide. Read on to learn more about innovative CAR-T cell therapy companies and the technologies they are using to fight cancer.
In this article:Â
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 339
- Next Page »